Sánchez-López Josefina Yoaly, Díaz-Herrera Luis Carlos, Rizo-de la Torre Lourdes Del Carmen
División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Mexico.
Servicio de Gastroenterología, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.
Arch Med Sci. 2024 Jun 28;20(3):1016-1021. doi: 10.5114/aoms/189971. eCollection 2024.
Atrophic gastritis and intestinal metaplasia are precursor lesions of gastric cancer. The aim of this study was to determine the usefulness of the biomarkers pepsinogen I(PgI), pepsinogen II (PgII), gastrin-17, and antibodies in the identification of precursor lesions.
We studied 129 patients with gastric symptoms. The biomarker status was determined using GastroPanel by means of the ELISA-technique.
Biomarkers detected atrophy in 14% of the subjects, and 49.6% had positive antibodies for . A PgI/PgII ratio < 3 was an important risk biomarker for precursor lesions in our population (OR = 9.171, 95% CI: 1.723-48.799, = 0.009); however, biomarkers showed low accuracy with histopathological study.
In the Western Mexican population, precursor lesions (AG, IM) are common in adults (45%) with dyspepsia but infrequent in children (8%). infection was detected in 41.3% of adults and 16.0% of children. Of the studied biomarkers, a PgI/PgII ratio < 3 was an important risk factor for precursor lesions such as AG or IM in our population, with an OR of 9.171 (95% CI: 1.723-48.799, = 0.009).
萎缩性胃炎和肠化生是胃癌的前驱病变。本研究的目的是确定生物标志物胃蛋白酶原I（PgI）、胃蛋白酶原II（PgII）、胃泌素-17及抗体在识别前驱病变中的作用。
我们研究了129例有胃部症状的患者。采用酶联免疫吸附测定（ELISA）技术通过胃功能检测（GastroPanel）来确定生物标志物状态。
生物标志物在14%的受试者中检测到萎缩，49.6%的受试者抗体检出呈阳性。在我们的研究人群中，PgI/PgII比值<3是前驱病变的一个重要风险生物标志物（比值比[OR]=9.171，95%置信区间[CI]：1.723 - 48.799，P=0.009）；然而，生物标志物与组织病理学研究相比准确性较低。
在墨西哥西部人群中，前驱病变（萎缩性胃炎、肠化生）在有消化不良症状的成年人中常见（45%），但在儿童中少见（8%）。41.3%的成年人及16.0%的儿童检测到感染。在所研究的生物标志物中，PgI/PgII比值<3是我们研究人群中萎缩性胃炎或肠化生等前驱病变的一个重要危险因素，OR为9.171（95%CI：1.723 - 48.799，P=0.009）。
